Richards, J S
Arias Vásquez, A
von Rhein, D
van der Meer, D http://orcid.org/0000-0002-0466-386X
Franke, B
Hoekstra, P J
Heslenfeld, D J
Oosterlaan, J
Faraone, S V
Buitelaar, J K
Hartman, C A
Article History
Received: 26 May 2015
Revised: 9 February 2016
Accepted: 11 February 2016
First Online: 5 April 2016
Competing interests
: In the past year, SVF received income, travel expenses and/or research support from and/or has been on an Advisory Board for Pfizer, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax, NeuroLifeSciences, and received research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium–hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. SVF receives royalties from books published by Guilford Press (<i>Straight Talk about Your Child’s Mental Health</i>) and Oxford University Press (<i>Schizophrenia: The Facts</i>). In the past 3 years, JKB has been a consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Shering Plough, UCB, Shire, Novartis and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents and royalties. In the past 3 years, PJH has been a consultant to/member of advisory board of Shire and has received an unrestricted investigator-initiated research grant from Shire. JO has received an unrestricted investigator initiated research grant from Shire. BF received a speaker fee from Merz. The remaining authors declare no conflict of interest.